KRMD at a glance
KORU Medical Systems, Inc. (KRMD, SEC CIK 704440) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 14, 2026 and Form 4 insider filings as recently as October 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), KORU Medical Systems, Inc. (KRMD) reported revenue of $41.1 million (up 22.2% from FY2024) and a net loss of $2.6 million. Diluted EPS was -$0.06.
- As of June 30, 2026, 20 institutional investment managers tracked by SignalX reported holding KORU Medical Systems, Inc. (KRMD) shares worth $28.4 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by KALBERMATTEN ADAM R on September 8, 2026 of 32,000 shares at $3.16 per share.
- In the last 90 days, KRMD insiders reported 1 open-market purchase ($101K) and 0 open-market sales ($0) on Form 4, a net purchase of $101K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $41.1M
- +22.2% vs prior year
- Insiders · 90 days
- 1 buy · 0 sells
- Net +$101K
- 13F holders
- 20 funds
- $28.4M · +0 vs prior quarter
- Latest 8-K
- Aug 14, 2026
- Item 5.03
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Q2 revenue $12.0M, up 18.2% YoY from $10.2M
- Gross margin 65.1% vs 63.5% YoY
- Best segment International Core $3.5M, up 59.1% YoY
- Worst segment Pharma Services $0.6M, down 35.0% YoY
- Cash $8.3M; six-month operating cash flow $0.2M vs $(0.7)M YoY
- Outlook: liquidity sufficient through next twelve months, with potential future debt or equity financing needs
Risk Factors
- No material changes in risk factors identified; 10-Q references risks from the December 31, 2025 Form 10-K
- Unregistered equity issuance risk from May 18 asset acquisition; 125,628 shares issued under Regulation D
- Share-transfer restriction risk; issued shares subject to an 18-month transfer restriction
AI summary of the KRMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Shareholder approval now required to remove directors, with majority of outstanding shares mandated
- Board’s removal authority eliminated under amended Section 3.05
Item 2.02: Results of Operations and Financial Condition
- Standard 8-K liability disclaimer; no earnings figures or operating results disclosed in the provided text
- Investor-relevant results, if any, are likely contained in an accompanying exhibit or separate earnings release
Item EX-99.1: Item EX-99.1
- Q2 revenue $12.0M, up 18.2%, led by international core growth of 59.1% and domestic core growth of 12.4%
- Gross margin improved to 65.1% from 63.5%, supporting gross profit growth of 21.2% to $7.8M
Item 1.01: Entry into a Material Definitive Agreement
- Supply agreement extended through December 31, 2031, supporting manufacturing continuity for subassemblies, needle sets, and tubing
- Command required to qualify a second manufacturing site by December 31, 2027, reducing single-site concentration risk
AI summaries of KRMD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for KRMD
Don't miss the next KRMD filing
- Alerts as it files. A push when KRMD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut KRMD, by share count.
- Ask anything. An AI agent that reads every KRMD filing and answers with sources.
KRMD alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| WHOLIHAN EDWARD | A | Oct 1, 2026 | 5,119 | $2.93 |
| CASCELLA ROBERT | A | Oct 1, 2026 | 5,119 | $2.93 |
| Matin Shahriar | A | Oct 1, 2026 | 5,119 | $2.93 |
| French Donna | A | Oct 1, 2026 | 5,119 | $2.93 |
| FLETCHER R JOHN | A | Oct 1, 2026 | 7,679 | $2.93 |
| Manko Joseph M. Jr. | A | Sep 30, 2026 | 5,119 | - |
| KALBERMATTEN ADAM R | Buy | Sep 8, 2026 | 32,000 | $3.16 |
| KALBERMATTEN ADAM R | F | Jul 28, 2026 | 25,483 | $4.26 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $28.5M | $33.6M | $41.1M |
| Gross Profit | $16.7M | $21.3M | $25.6M |
| Operating Income | - | -$6.4M | -$3.0M |
| Net Income | -$13.7M | -$6.1M | -$2.6M |
| Gross Margin | 58.6% | 63.4% | 62.3% |
| Op. Margin | - | -19.2% | -7.2% |
| Net Margin | -48.2% | -18.0% | -6.4% |
| Balance Sheet | |||
| Total Assets | - | $27.2M | $28.2M |
| Equity | $20.4M | $16.8M | $17.0M |
| ROE | -67.5% | -36.1% | -15.5% |
| Per Share | |||
| EPS | - | $-0.13 | $-0.06 |
| Cash Flow | |||
| Operating CF | - | -$320K | $462K |
Source: XBRL data in KORU Medical Systems, Inc. (KRMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate KRMD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 20 | $28.4M |
| Q1 2026 | 20 | $27.6M |
| Q4 2025 | 18 | $38.0M |
| Q3 2025 | 17 | $22.5M |
| Q2 2025 | 20 | $20.3M |
| Q1 2025 | 16 | $8.9M |
| Q4 2024 | 10 | $9.7M |
| Q3 2024 | 7 | $2.2M |
- BlackRock+256.5K (+11%)
- Vanguard Capital Management LLC+131.9K (+8%)
- Renaissance Technologies LLC+119.0K (+259%)
- Vanguard Portfolio Management LLC+54.4K (+21%)
- Wells Fargo & Co+25.4K (+162%)
- Goldman Sachs Group−125.3K (-55%)
- Two Sigma Investments−77.0K (-84%)
- Morgan Stanley−46.1K (-12%)
- Citadel Advisors LLC−20.2K (-41%)
- Bank of America Corp−8.4K (-22%)
- Millennium Management+16.4K
- Prudential Financial−12.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 128 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
KRMD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 8-K | Aug 14, 2026 | - | Analysis | - |
| 4 | Aug 6, 2026 | - | - | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Jul 29, 2026 | - | - | |
| 4 | Jul 13, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | May 21, 2026 | - | Analysis | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 20, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
KRMD SEC filings: frequently asked questions
Are KRMD insiders buying or selling?
In the last 90 days, KORU Medical Systems, Inc. (KRMD) officers, directors and 10% owners reported 1 open-market purchase worth $101,120 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold KRMD stock?
As of June 30, 2026, the largest KORU Medical Systems, Inc. (KRMD) holders among the 13F filers tracked by SignalX were BlackRock ($11.0 million), Vanguard Capital Management LLC ($7.6 million), State Street Corp ($2.7 million), Northern Trust ($1.5 million), Morgan Stanley ($1.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was KRMD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), KORU Medical Systems, Inc. (KRMD) reported revenue of $41.1 million (up 22.2% from FY2024) and a net loss of $2.6 million. Diluted EPS was -$0.06. The figures come from the XBRL data in the 10-K.
What did KRMD report in its latest 8-K?
KORU Medical Systems, Inc. (KRMD) filed an 8-K on August 14, 2026 reporting Item 5.03 (Amendments to Articles of Incorporation or Bylaws). Shareholder approval now required to remove directors, with majority of outstanding shares mandated.
What are the latest KRMD SEC filings?
KORU Medical Systems, Inc. (KRMD) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 14, 2026 and a Form 4 insider filing on October 1, 2026.
What is KRMD's SEC CIK number?
KORU Medical Systems, Inc. (KRMD)'s SEC Central Index Key (CIK) is 704440. EDGAR lists every KRMD filing under that number.
Ask anything about KRMD
The research agent reads KRMD's filings, financials, insider trades and 13F holders, then answers with sources.